These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28674251)

  • 1. Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.
    Mukai Y; Narita M; Akiyama E; Ohashi K; Horiuchi Y; Kato Y; Toda T; Rane A; Inotsume N
    Biol Pharm Bull; 2017; 40(7):1078-1085. PubMed ID: 28674251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
    Transon C; Leemann T; Dayer P
    Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.
    Zhou Q; Ruan ZR; Yuan H; Zeng S
    Arzneimittelforschung; 2012 Nov; 62(11):519-24. PubMed ID: 22941809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.
    Toda T; Eliasson E; Ask B; Inotsume N; Rane A
    Basic Clin Pharmacol Toxicol; 2009 Nov; 105(5):327-32. PubMed ID: 19663817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
    Lee CK; Choi JS; Choi DH
    Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
    Misaka S; Abe O; Sato H; Ono T; Shikama Y; Onoue S; Yabe H; Kimura J
    Eur J Clin Pharmacol; 2018 May; 74(5):601-609. PubMed ID: 29368187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.
    Meyer zu Schwabedissen HE; Siegmund W; Kroemer HK; Rollnik JD
    BMC Res Notes; 2014 Oct; 7():688. PubMed ID: 25280537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
    Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Woman Experienced Severe Thrombocytopenia When Treated With Fluvastatin].
    Potier A; Dony A; Crapsky A; Ferry O; Piney D; Dufay E
    Therapie; 2015; 70(6):541-4. PubMed ID: 26238127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
    Filppula AM; Mustonen TM; Backman JT
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits.
    Kim Y; Park K; Kang W
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):443-9. PubMed ID: 20809476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study.
    Siepmann T; Heinke D; Kepplinger J; Barlinn K; Gehrisch S; Grählert X; Schwanebeck U; Reichmann H; Puetz V; Bodechtel U; Gahn G
    Br J Clin Pharmacol; 2014 Nov; 78(5):1058-66. PubMed ID: 24803100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of the biopharmaceutical properties of fluvastatin.
    Deslypere JP
    Am J Cardiol; 1994 May; 73(14):12D-17D. PubMed ID: 8198018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.